Targeted Labs Chronic Migraine: Understanding Your Needs

Using Targeted Labs to Identify Modifiable Contributors Before or Alongside Botox for Chronic Migraine

Maria had kept a careful headache diary for three months. Most days started with pressure behind one eye that later became a full migraine with nausea and light sensitivity. She averaged 18 headache days per month. Her primary doctor confirmed the pattern met the definition of chronic migraine, and she was now considering FDA-approved onabotulinumtoxinA (Botox) for prevention. At the same time, she wondered whether inflammation, blood-sugar swings, or hormone changes were quietly raising her headache frequency. She wanted to address those factors without delaying proven care.

This is a common situation for patients whose headaches have become frequent. Targeted laboratory panels can identify modifiable contributors that may influence how often migraines occur, while the clinical record continues to document the 15-or-more-headache-day threshold required for guideline-based prevention. The goal is clearer information and practical next steps, not a claim that labs alone prove or disprove migraine.

Chronic Migraine and the Path to Guideline-Based Prevention

The International Classification of Headache Disorders, Third Edition (ICHD-3) defines chronic migraine. It involves headaches on 15 or more days per month for more than three months, with migraine features present on at least eight of those days, in a person who has a prior history of migraine. The headaches must not be better explained by another disorder. FDA labeling for onabotulinumtoxin A specifies adults who experience at least 15 headache days per month lasting four hours or longer. Safety and effectiveness have not been established for episodic migraine (14 or fewer headache days).

The Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) trials established the evidence base. Patients received 155 units of onabotulinumtoxinA injected across 31 sites in seven head and neck muscle regions every 12 weeks. Pooled data showed an average reduction of about 8.4 headache days from baseline at week 24 compared with 6.6 days on placebo. Current guidelines support onabotulinumtoxinA with high-confidence evidence for reducing headache frequency in chronic migraine. Full details of patient selection, injection technique, and follow-up appear in the clinic’s BOTOX Chronic Migraine Treatment: 2026 Clinical Guide at https://dralexjimenez.com/?p=382207.

Laboratory results do not replace this diagnostic process. They provide additional context that you can review before the first treatment cycle or as ongoing diary data confirm the frequency threshold.

How Inflammation, Metabolism, and Hormones Can Influence Headache Frequency

Migraine involves the trigeminovascular system and neuropeptides such as calcitonin gene-related peptide (CGRP). Supporting cells and immune signaling molecules can participate in a process sometimes described as neuroinflammation. This is not the same as ordinary tissue inflammation that produces swelling and redness after an injury. Still, higher levels of certain circulating markers have been observed in some people with frequent migraine, and metabolic conditions such as insulin resistance are associated with low-grade inflammatory signaling.

Hormonal shifts are relevant for many patients. Declining estrogen before menstruation is a recognized trigger for menstrual migraine. Thyroid dysfunction can produce fatigue, sleep disruption, and headaches that overlap with migraine symptoms. Nutrient status also plays a role. Observational work has linked lower magnesium, riboflavin (vitamin B2), or coenzyme Q10 levels to higher migraine burden, and correcting clear deficiencies is a low-risk step many patients take.

None of these findings prove that a laboratory abnormality caused an individual patient’s migraines. They simply identify modifiable factors that clinical guidelines already consider relevant during a full evaluation. Addressing them can support the same goal as Botox: fewer headache days and better daily function.

Targeted Panels That Help Confirm or Address Co-Factors

At Injury Medical Clinic PA, laboratory testing is ordered under the medical direction of Dr. Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine. Common panels reviewed in the context of frequent migraine include:

• Inflammatory markers: high-sensitivity C-reactive protein (hs-CRP) and, when indicated, selected cytokines. Elevated results may prompt dietary, sleep, or metabolic work rather than immediate medication changes.
• Metabolic markers: fasting glucose, HbA1c, fasting insulin, and a lipid panel. These help identify insulin resistance or related patterns linked to higher migraine frequency.
• Hormonal assessment: thyroid-stimulating hormone (TSH) with free T4, and, when the history suggests it, sex hormone timing or cortisol patterns. Results guide whether endocrine care is needed; they do not automatically treat migraine.
• Nutrient status: serum magnesium, vitamin B12, ferritin, and sometimes riboflavin or coenzyme Q10 levels. Clear deficiencies can be corrected with straightforward supplementation while other therapies proceed.

Choose these tests after history and examination, not as a routine screen for every headache patient. Interpret results alongside the headache diary so the frequency threshold and any co-factors remain visible in the record. Patients who already meet criteria for onabotulinumtoxinA can begin or continue treatment while addressing laboratory findings. Patients who are still gathering diary data can use the same panels to reduce potential contributors before the first injection cycle.

The clinic’s Integrated Migraine Treatment guide at https://dralexjimenez.com/?page_id=382168 expands on how laboratory findings fit within a broader evaluation that also includes neurological screening and cervical assessment. Related discussion of neuroinflammatory pathways appears in Regenerative Therapies and Solutions for Neuroinflammation at https://dralexjimenez.com/regenerative-therapies-and-solutions-for-neuroinflammation/.

Documenting the Threshold While Addressing Co-Factors

A simple daily diary remains the core tool for confirming the 15-day threshold. Entries note headache presence or absence, severity, associated symptoms, acute medication use, and any clear triggers. When laboratory results return, add them to the same chart. This creates a continuous record that shows both the pattern required for guideline-based prevention and the steps taken to manage modifiable factors.

For patients whose migraines began or worsened after trauma, the same diary and timed laboratory data help distinguish the post-injury trajectory from earlier baseline patterns. The dual-scope notes—soft-tissue and functional findings coordinated with internal-medicine oversight—support clear communication with treating physicians and, when relevant, with legal counsel. These objective markers support comprehensive pathways detailed at https://dralexjimenez.com.

Bioethical Foundations of Combined Care

Three principles guide the process.

Beneficence means the plan targets root-cause support and proven prevention. Correcting an iron deficiency or improving insulin sensitivity does not replace Botox when criteria are met; it works alongside it so the patient gains the greatest practical reduction in headache days.

Non-maleficence favors options that limit additional medication burden. Targeted nutrition, lifestyle adjustments, and guideline-approved preventive injections reduce the chance that patients accumulate multiple daily oral preventives with overlapping side effects.

Autonomy positions the patient as an informed decision-maker. The team reviews laboratory results and the headache diary together. Patients see the numbers, understand what each test can and cannot show, and choose whether to start or continue onabotulinumtoxinA while addressing other factors. Coordination with existing primary-care or specialty teams remains seamless.

What Makes the Clinic Unique in El Paso

Dr. Jimenez’s Injury Medical Chiropractic and Functional Medicine Clinic is the only practice in El Paso that combines a medical director, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine, Texas License #J2933), with a dual-licensed nurse practitioner specializing in soft-tissue injury. Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP (Texas License #1191402, Prescriptive Authority #59628), bridges structural and functional care. This integrated model allows laboratory panels ordered under internal-medicine oversight to be interpreted in the same setting where cervical mechanics, soft-tissue findings, and headache-diary data are documented. Patients receive coordinated recommendations for inflammation, metabolic, and hormonal contributors while the clinical record remains ready for both treatment decisions and, when applicable, medical-legal review.

Patients who want to explore these options can schedule a consultation to review their diary, discuss laboratory priorities, and determine whether they already meet criteria for guideline-based prevention or still need additional documentation. The same visit coordinates soft-tissue evaluation with internal-medicine oversight so that both the frequency threshold and any modifiable co-factors stay visible in one record. Call the office or visit the scheduling page to begin. These objective markers support comprehensive pathways detailed at https://dralexjimenez.com.

---

References

Headache Classification Committee of the International Headache Society (IHS). (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1–211. https://doi.org/10.1177/0333102417738202

Dodick, D. W., Turkel, C. C., DeGryse, R. E., Aurora, S. K., Silberstein, S. D., Lipton, R. B., Diener, H.-C., & Brin, M. F. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache, 50(6), 921–936. https://doi.org/10.1111/j.1526-4610.2010.01678.x

Aurora, S. K., Dodick, D. W., Turkel, C. C., DeGryse, R. E., Silberstein, S. D., Lipton, R. B., Diener, H.-C., & Brin, M. F. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia, 30(7), 793–803. https://doi.org/10.1177/0333102410364676

Potrebic, S., Tanveer, S., Becker, W. J., Burch, R., Cooke, L. J., Fenton, T., Fletcher, J. J., Gordon Perue, G. L., Hershey, A. D., Jackson, J. L., Kessel, S., Loder, E. W., Minen, M. T., Oskoui, M., Ramanan, V. K., Murren, M., Schwedt, T. J., Silberstein, S. D., Smith, D. B., … Pringsheim, T. (2026). Pharmacologic treatment for migraine prevention in adults practice guideline recommendations. Headache, 66(9), 2173–2184. https://doi.org/10.1111/head.70199

AbbVie Inc. (2024). BOTOX (onabotulinumtoxinA) for injection, for intramuscular use [Prescribing information]. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103000s5320lbl.pdf

Cavestro, C. (2025). Metabolic dysfunction and dietary interventions in migraine management: The role of insulin resistance and neuroinflammation—A narrative and scoping review. Brain Sciences, 15(5), Article 474. https://doi.org/10.3390/brainsci15050474

Rivera-Mancilla, E., Al-Hassany, L., Villalón, C. M., & MaassenVanDenBrink, A. (2021). Metabolic aspects of migraine: Association with obesity and diabetes mellitus. Frontiers in Neurology, 12, Article 686398. https://doi.org/10.3389/fneur.2021.686398

Rainero, I., Govone, F., Gai, A., Vacca, A., & Rubino, E. (2018). Is migraine primarily a metaboloendocrine disorder?. Current Pain and Headache Reports, 22(5), Article 36. https://doi.org/10.1007/s11916-018-0691-7